KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Assets: 2011-2025

Historic Assets for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $1.4 billion.

  • Supernus Pharmaceuticals' Assets rose 5.74% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 5.74%. This contributed to the annual value of $1.4 billion for FY2024, which is 7.08% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Assets is $1.4 billion, which was up 2.70% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Assets registered a high of $1.8 billion during Q1 2023, and its lowest value of $1.3 billion during Q4 2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Assets value was $1.3 billion (recorded in 2024), while the average stood at $1.4 billion.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Assets rose by 26.69% in 2021, and later decreased by 27.22% in 2024.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Assets stood at $1.7 billion in 2021, then climbed by 0.79% to $1.7 billion in 2022, then declined by 24.95% to $1.3 billion in 2023, then rose by 7.08% to $1.4 billion in 2024, then increased by 5.74% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.3 billion during Q1 2025.